Skip to main content
. 2018 Mar 14;11:1756284818759930. doi: 10.1177/1756284818759930

Figure 3.

Figure 3.

C-reactive protein (CRP) concentrations in patients with serum adalimumab concentrations of less than 5 mg/liter versus at least 5 mg/liter in all patients (31 versus 93) (A), in patients with ulcerative colitis (UC) (3 versus 20) (B), and in patients with Crohn’s disease (CD) (28 versus 73) (C). Medians and ranges are shown.